Exploring Real-World HER2-Low Data in Early-Stage Triple-Negative Breast Cancer: Insights and Implications.
Jessé Lopes da SilvaGiselle de Souza CarvalhoLucas Zanetti de AlbuquerqueFabiana Resende RodriguesPriscila Valverde FernandesDaniel KischinhevskyAndreia Cristina de MeloPublished in: Breast cancer (Dove Medical Press) (2023)
The findings of this study suggest that, in early-stage TNBC, the clinical behavior and survival outcomes of the HER2-low subgroup may not differ significantly from those of the HER2-zero subgroup.